Management of thrombocythemia

INFERIOR VENA CAVA THROMBOSIS IN A PATIENT WITH ESSENTIAL THROMBOCYTHEMIA

Essential thrombocythemia is a chronic myeloproliferative disorder characterized by a sustained proliferation of megakaryocytes, which leads to increased numbers of circulating platelets. Hemorrhagic and/or thrombotic episodes are frequent, and thrombosis of both veins and arteries may develop. Vessels in unusual sites may be involved, e.g., the hepatic veins, mesenteric veins, and the dig...

Successful Management of Hydroxyurea-induced Leg Ulcers in Essential Thrombocythemia: Report of 3 Cases

Essential thrombocythemia is one of the myeloproliferative neoplasms with a plethora of thrombohemorrhagic complications.Hydroxyurea has been proven to be an effective treatment for this condition. However, it is not without side effects. We herein report 3 patients with essential thrombocythemia treated with hydroxyurea who developed refractory leg ulcers, and we outline their successful manag...

Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?

Pathogenesis and management of essential thrombocythemia.

The last four years have seen an explosion in our understanding of the myeloproliferative neoplasms. Important and often unexpected insights into the molecular mechanisms responsible for these disorders have been accompanied by the development of new diagnostic tests and by an improved understanding of the relationship between the different disease entities. This review will focus on recent dev...

Pretreatment with hydroxyurea of the patient with essential thrombocythemia followed by coronary artery bypass surgery.

The risk of thrombosis is high in patients with essential thrombocythemia. Special precaution needed for those patients who will undergo Coronary artery bypass grafting. We are reporting a 62 years old patient with ischemic heart disease who was found to have essential thrombocythemia. This report explains the preoperative management and the postoperative risks anticipated due to the treatment.

Aortic valve replacement for a patient with essential thrombocythemia: a case report.

A 51-year-old male patient with 3+ aortic insufficiency, hepatitis C, osteomyelitis right foot, and a preoperative platelet count 1.3 million/mm3 required cardiopulmonary bypass (CPB). Essential thrombocythemia is a relatively unknown entity with the utilization of CPB. After consulting with the surgeon, an anesthesiologist and another perfusionist, a team approach was used to discuss treatment...